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Abstract
Background: Yaws is a bacterial skin and bone infectious disease caused by Treponema pallidum pertenue.I ti s
endemic, particularly among pygmies in Central African Republic. To assess the clinical cure rate after treatment
with benzathinepenicillin in this population, we conducted a cohort survey of 243 patients in the Lobaye region.
Findings and conclusion: The rate of healing of lesions after 5 months was 95.9%. This relatively satisfactory level
of therapeutic response implies that yaws could be controlled in the Central African Republic. Thus, reinforcement
of the management of new cases and of contacts is suggested.
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Background
Yaws is a skin and bone non-venereal treponematosis
caused by Treponema pallidum subsp. pertenue.I ti s
not considered a neglected disease, but a forgotten one
[1,2]. Most infected people reside in warm, humid tropi-
cal areas, in communities with lack of hygiene [3]. The
usual means of transmission of yaws is close bodily con-
tact with a patient with infectious lesions [4]. The clini-
cal features are classified in stages [1,5]. During the
primary stage, a lesion called the ‘mother yaw’ occurs as
a papule, which develops after 2-4 weeks of incubation
at the site of Treponema inoculation and enlarges before
it ulcerates. Spontaneous resolution occurs after almost
6 months, and the initial lesion heals. The secondary
stage is characterized by widespread smaller skin
papules, the ‘daughter yaws’. After a variable latency,
which can last several years, a late stage develops in 10%
of patients, which consists of skin ulceration, gumma
formation and destruction of bones and cartilage.
Painful palmoplantar hyperkeratosis and keratoderma
are also observed during this third stage.
Basically, the diagnosis of an infection by Treponema
pertenue is based on three criteria,(i) the emergence of
the disease in an endemic region, (ii) clinically typical
papilloma lesions, and (iii) seroactivity in a treponemal
antigen test [6]. The operational definition of a case of
yaws is “any person who lives in an endemic area and
presents with one or more of the following signs: pain-
less ulcer with scab, papilloma, palmar/plantar hyperker-
atosis (thickening)” [2].
Clinical diagnosis is reliable with minimal training of
health staff. In the field, diagnosis is based mainly on
clinical findings and epidemiology. The diagnostic terms
suggestive of active yaws proposed for use in mass cam-
paigns [7-9] are (i) initial lesions of nongenital chancre,
painless, non-tender papule with a raised margin; (ii)
multiple papillomata; (iii) plantar and palmar papillo-
mata; (iv) hyperkeratosis and (v) gummata, ulcers and
gangosa.
The elimination and ultimate eradication of the infec-
tion require strategies targeted against the factors that
favour its transmission. Thus, control activities must be
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the source of infection, with improved environmental
and individual hygiene [10]. Benzathinebenzylpenicillin
is the currently recommended antibiotic for use against
yaws [11].
Mass campaigns carried out in yaws endemic areas
since the 1950’s gave rise to the possibility of eradication
of this infection [11,12]. Recently, however, resurgence
of yaws has been reported [13-15], due to curtailment of
control activities, which has allowed the reservoir of
untreated yaws to grow unchecked.
Yaws is endemic in central Africa [16]. In the Cen-
tral African Republic (CAR), pygmies are the most
widely infected segment of the population [6]. In a
serological survey performed between November 1978
and March 1979 in the pygmy population of south-
west CAR (Lobaye and Sangha), the prevalence of
clinically diagnosed yaws was 50%, with positive serol-
ogy rates of 86% in children and 95% in adults [17].
In the same area, Cirera et al. showed that 78.5% of
pygmy children had sera positive for Treponema,s u g -
gesting massive infestation with T. pertenue [18].
Mass treatment campaigns were carried out in those
regions between 1977 and 1980 (CAR Health Ministry,
unpublished data). In 1992, a resurgence of yaws was
reported in this area [15], but no further control activ-
ities were conducted.
Treatment of yaws with benzathinebenzylpenicillin is
included in CAR Ministry of Health guidelines; however,
the outcome of patients treated with this antibiotic has
never been assessed. The aim of this study was to evaluate
the clinical evolution of yaws skin lesions after administra-
tion of benzathinebenzylpenicillin in a pygmy population.
Methods
Study area
A treatment campaign against yaws was conducted in
Mongoumba (Figure 1), a district in the Lobaye region
in southwest CAR close to the borders with the Demo-
cratic Republic of the Congo and the Congo. The cli-
mate is equatorial. The total population is estimated at
21 235 inhabitants, 15% (n = 3089) of whom are pyg-
mies. In this area, there are two health centres: the
Santé Saint Georges, which is a private health centre
run by Comboni Missionaries whose aim is to improve
the social integration of pygmies; and the Mongoumba
Health Centre, which is a public institution of the CAR
Ministry of Health.
Staff of Santé Saint Georges visit pygmies in their set-
tlements, dispersed throughout the forest, to advise
Figure 1 Study location, Mongoumba, Central African Republic.
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to present themselves to either the Santé Saint Georges
or the Mongoumba health centre.
Case diagnosis
Between November 2007 and March 2008, a cohort of
pigmies presenting with skin lesions was constituted.
The inclusion criteria were skin lesions clinically sugges-
tive of yaws or any other non-traumatic skin lesions
that could not be classified but which scored positive on
serological analysis with both the venereal disease
research laboratory (VDRL) test and the T. pallidum
haemagglutination (TPHA) test.
All 254 pygmies in 18 settlements in the Mongoumba
region with these types of skin lesion were recruited. Of
these, 191 had skin lesions clinically suggestive of yaws,
and 63 had other skin lesions. Assuming that Trepo-
nema serology was likely to be positive in people with
skin lesions clinically suggestive of yaws [17,18], we did
not collect blood samples for serological diagnosis in
these cases; however, a 5-ml venous blood sample was
collected from each of the 63 pygmies with atypical skin
lesions and tested at the Institut Pasteur de Bangui.
Both tests were positive in 52 patients, three were posi-
tive with TPHA and negative with VDRL, and eight
samples were negative with both tests. The patients
positive in both tests were considered to have active
yaws. Thus, a cohort of 243 patients was constituted to
assess scarring of skin lesions after injection of one dose
of benzathinebenzylpenicillin.
Treatment and follow-up
During April 2008, a single dose of benzathinebenzylpe-
nicillin was administered intramuscularly to each of the
243 patients in our study cohort and to contacts not
presenting any skin lesions. The doses administered
were 2.4 M units for adults, 1.2 M units for children
and 0.6 M units for infants. Some pygmies were absent
during this treatment campaign. Hence, a total of 2456
pygmies in the Mongoumba area (79.5% or 2456/3089)
were treated during the 6-month campaign. Follow-up
of those pigmies with skin lesions was conducted at the
Santé Saint Georges health centre, with no follow-up in
the settlements. Clinical outcome (total scarring of skin
lesions) was assessed 2-5 months later (July-September
2008).
Ethical approval and consent to participate
Because there was no national ethical committee in the
CAR during the period in which this survey was con-
ducted, the project was approved by the expert commit-
tee for drug policy and the Ministry of Health in the
C A R .T h ea i mo ft h es u r v e ya n da l lt h ep r o c e d u r e s
(clinical examination, probable collection of blood
samples for laboratory investigation of yaws, injection of
the antibiotic into the gluteal muscle, use of photo-
graphs for possible publication and duration of follow-
up) were explained in the native Aka language during
meetings organized by our study team. Oral consent
was collected from all participants, none of whom was
literate.
Findings
In this study, we observed no lost of follow-up. The
mean age of patients was 16 years (median, 20 years)
and the male: female ratio was 1.15. Initial yaws skin
lesions were found in 135 (55.6%) cases, multiple papil-
lomata (Figure 2) in 12.3%, plantar and palmar papillo-
mata in 5.3%, hyperkeratosis in 2.5% and ulcers in 2.9%;
the remaining cases, classified as atypical lesions, repre-
sented 21.4%. There was no statistically significant dif-
ference in the distribution of clinical stages by sex (p =
0.6). Initial yaws lesions were more frequent among chil-
dren < 17 years (74.5% or 82/110) than in other age
categories (p < 0.0001) (Figure 3).
Overall, 95.9% (233/243) of the skin lesions had
scarred during the period before outcome assessment
(Figure 4); 10 patients presented with persistent skin
lesions at the end of assessment, all located on the feet
and complicated by ulcers. These persistent lesions had
been classified at baseline as initial lesions (5.2% or 7/
135), multiple papillomata (3.3% or 1/30) and atypical
skin lesions (3.8% or 2/52). Persistent lesions were fol-
lowed up and dressed regularly at the Santé Saint
Georges health centre.
The additional file 1 (as Excel xls file) provide details
on data of this study.
Discussion
There is a suspected emergence of Treponema pertenue
resistance to benzathinebenzylpenicillin [19]. Hence, it
was essential to assess clinical evolution of skin lesions
of yaws after treatment with benzathinebenzylpenicillin.
Our findings show that relatively few skin lesions per-
sisted 5 months after administration of benzathineben-
zylpenicillin in this study cohort. The persistent lesions
might be treatment failures due to concurrent factors
such as other infecting agents and microtrauma. All the
persistent lesions were located on the feet, which are
highly exposed because pygmies rarely wear shoes and
their economy is based on hunting in the equatorial for-
est. It is possible that T. pallidum pertenue developed
resistance to benzathinebenzylpenicillin in these cases,
as reported by Backhouse in Papua New Guinea [19,20].
A potential limitation of this study is that serological
tests were not performed systematically in all patients to
support a diagnosis of yaws, and clinical diagnosis might
have led to overestimation of the number of cases. In
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predictive of yaws [17]. Moreover, we found 82.5% posi-
tive serology with both VDRL and TPHA in patients
with atypical lesions clinically suggestive of yaws. A sec-
ond potential limitation is that the outcome was not
assessed from VDRL titres after treatment but only
from healing of skin lesions. Use of VDLR titres could
be justified in chronic infections involving the bones
[19], because of low bone penetration of penicillin [21].
Scarring of skin lesions can be attributed to killing of
the microbes by benzathinebenzylpenicillin a few
months after its administration to patients, even if spon-
taneous resolution of some primary lesions occurred.
Moreover, no new skin lesions suggestive of yaws were
registered at Santé Saint Georges or in the pygmy settle-
ments at the time we measured clinical outcome. There-
fore, the mass campaign with benzathinebenzylpenicillin
prevented any new infections, suggesting its efficacy.
The high proportion (26.5%) of initial lesions in peo-
ple aged over 17 years is surprising. In this region, a
diagnosis of yaws can be differentiated from primary
lesions of tropical ulcers [22,23], hence, usefulness of
serological tests to overcome this difficulty with
diagnosis.
Although the coverage rate of our mass treatment
campaign was almost 80%, there could be latent yaws
lesions in the untreated pygmies, constituting a source
of resurgence of active yaws lesions in Mongoumba.
The scarring rate observed in this cohort survey indi-
cates that mass campaigns could eradicate this infec-
tious disease. It is, however, not easy to give health
advice to pygmies who live in the forest. Continued
interruption of transmission and eradication depend on
the availability of personnel and environmental
sanitation.
Conclusion
This survey showed a high rate of efficacy of benzathi-
nebenzylpenicillin in healing yaws. Our findings also
show that yaws is presumably still highly prevalent in
this area, especially in the pygmy population, due to
their poor personal and environmental hygiene. As
spread of this infection to other contact groups in the
country is possible, ongoing activities to improve social
conditions and surveillance and prompt treatment of
new yaws cases and all contacts are necessary in the
endemic areas of CAR. The CAR health Ministry should
introduce yaws control activities in the primary health
Figure 2 Active yaws lesions, Mongoumba, Central African Republic, December 2007 (photograph by S.V. Boas).
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Figure 3 Age distribution by stage of yaws in 243 patients, Central African Republic, December 2007-September 2008.
Figure 4 Clinical healing after treatment of yaws in 243 patients, Central African Republic, December 2007-September 2008.
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of benzathinebenzylpenicillin are also needed, with
assessment of the bone stage of yaws.
Additional material
Additional file 1: Clinical yaws stage: A, initial lesions; B, multiple
papillomata; C, plantar and palmar papillomata; D, hyperkeratosis;
E, gummata, ulcers or gangosa; F, atypical skin lesions.
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